Angiogénesis
Los inhibidores de la angiogénesis son compuestos que interfieren con la formación de nuevos vasos sanguíneos, un proceso crucial en el crecimiento y la metástasis del cáncer. Al inhibir la angiogénesis, estos compuestos pueden restringir el suministro de sangre a los tumores, ralentizando o deteniendo su crecimiento. Los inhibidores de la angiogénesis son esenciales en la investigación del cáncer y en el desarrollo terapéutico, proporcionando información sobre los mecanismos de progresión tumoral y ofreciendo posibles tratamientos para el cáncer y otras enfermedades relacionadas con la angiogénesis. En CymitQuimica, ofrecemos una amplia gama de inhibidores de la angiogénesis de alta calidad para apoyar su investigación en oncología y biología vascular.
Subcategorías de "Angiogénesis"
- BTK(146 productos)
- Bcr-Abl(102 productos)
- EGFR(572 productos)
- FAK(72 productos)
- FLT(92 productos)
- Receptor del factor de crecimiento de fibroblastos (FGFR)(169 productos)
- JAK(245 productos)
- PDGFR(126 productos)
- RAAS(87 productos)
- Src(79 productos)
- Syk(37 productos)
- Trombina(47 productos)
- VDA(2 productos)
- VEGFR(268 productos)
Mostrar 6 subcategorías más
Se han encontrado 1431 productos de "Angiogénesis"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
TL13-110
CAS:<p>Negative control for TL 13-112 . Displays no degradation of ALK in cell lines. Highly potent ALK inhibitor (IC50 = 0.34 nM).</p>Fórmula:C49H62ClN9O9SForma y color:SolidPeso molecular:988.59Pacritinib citrate
CAS:<p>Pacritinib (SB1518) citrate effectively inhibits wild-type JAK2 (IC 50 =23 nM) and the JAK2 V617F mutant (IC 50 =19 nM). It also targets FLT3 (IC 50 =22 nM) and the FLT3 D835Y mutant (IC 50 =6 nM). This compound is utilized in the study of acute myeloid leukemia (AML) and myelofibrosis (MF) [1] [2] [3].</p>Fórmula:C34H40N4O10Forma y color:SolidPeso molecular:664.7AST5902
CAS:<p>AST5902 is the active metabolite of Alflutinib.</p>Fórmula:C27H29F3N8O2Pureza:98%Forma y color:SolidPeso molecular:554.57Lyso-Monosialoganglioside GM3
CAS:<p>Lyso-Monosialoganglioside GM3 (Lyso-GM3) is an analog of Ganglioside GM3 with antitumor properties. It inhibits the increase in EGFR kinase activity induced by EGF in A431 epithelial cancer cells.</p>Fórmula:C41H74N2O20Forma y color:SolidPeso molecular:915.028AKN-028
CAS:<p>AKN-028 is an orally active and potent FLT3 tyrosine kinase inhibitor ( IC 50 = 6 nM). AKN-028 causes dose-dependent inhibition of FLT3 autophosphorylation.</p>Fórmula:C17H14N6Pureza:99.88%Forma y color:SolidPeso molecular:302.33SNIPER(ABL)-024
CAS:<p>SNIPER(ABL)-024, a compound that conjugates GNF5 (ABL inhibitor) to an LCL161 derivative (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels,</p>Fórmula:C52H61F3N8O9SPureza:98%Forma y color:SolidPeso molecular:1031.15IOX2-NH2-Methyl
<p>IOX2-NH2-Methyl is a modified form of IOX2. IOX2 is a specific inhibitor of PHD2 (prolyl-hydroxylase-2), capable of upregulating HIF-1α expression and suppressing ROS production. IOX2-NH2-Methyl is employed in investigations of platelet and thrombus formation.</p>Fórmula:C20H19N3O5Pureza:97.64% - 99.31%Forma y color:SolidPeso molecular:381.39EGFR-IN-83
<p>EGFR-IN-83 (Compound 9), an EGFR inhibitor with an IC50 of 2.53 nM, exhibits antiproliferative effects on MCF-7 and MDA-MB-231 cell lines, with respective IC50</p>Fórmula:C22H17F3N4OPureza:98%Forma y color:SolidPeso molecular:410.39Anticancer agent 271
<p>Anticanceragent 271 (compound 5C) exhibits antiproliferative activity against lung cancer (A549), colon cancer (Caco-2) cell lines, and human lung fibroblasts (WI38), with an IC50 value of 9.18 μM for A549 cells. This compound can downregulate PI3K and mTOR gene expression and is applicable in cancer research.</p>Forma y color:Odour SolidMC-Val-Cit-PAB-Amide-TLR7 agonist 4 Conjugate
CAS:<p>MC-Val-Cit-PAB-Amide-TLR7 agonist 4 Conjugate is a conjugate formed by linking MC-Val-Cit-PAB-Amide and TLR7 agonist 4, useful for cancer research.</p>Fórmula:C52H72N12O11Pureza:97.70%Forma y color:SolidPeso molecular:1041.2DSPE-PEG5000-A7R
<p>DSPE-PEG5000-A7R is a PEG compound composed of DSPE and the tumor vascular targeting peptide (A7R). The peptide A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors.</p>Forma y color:Odour SolidAD57
CAS:<p>AD57 is a potent inhibitor of both c-Src and Abl with IC50 of 0.025 μM and 0.041 μM, respectively.</p>Fórmula:C22H20F3N7OPureza:99.05%Forma y color:SoildPeso molecular:455.44Ibrutinib-biotin
CAS:<p>Ibrutinib-biotin probe links Ibrutinib to biotin, with IC50 0.755-1.02 nM for BTK (patent WO2014059368A1).</p>Fórmula:C56H80N12O9SPureza:98%Forma y color:SolidPeso molecular:1097.39PROTAC BCR-ABL1 ligand 1
CAS:<p>GMB-475 is a PROTAC ligand targeting BCR-ABL1 for degradation via E3 ligase recruitment.</p>Fórmula:C17H12F3N3O2Forma y color:SoildPeso molecular:347.29ALK protein ligand-1
CAS:<p>ALK protein ligand-1 (Compound A1) is an ALK protein ligand, acting as a ligand for the target protein in PROTACs, demonstrating inhibitory effects on ALK. It is also useful in the synthesis of AP-1.</p>Fórmula:C24H29ClN6O3SForma y color:SolidPeso molecular:517.043TLT8
<p>TLT8 is a ByeTAC protein degrader that targets BTK. It induces BTK degradation by non-covalently binding to Rpn-13 and BTK. TLT8 is applicable in research on chronic lymphocytic leukemia.</p>Forma y color:Odour SolidBTK ligand-14
<p>BTKligand-14 is a PROTAC-targeting ligand for BTK, suitable for the synthesis of FDU73.</p>Forma y color:Odour SolidEGFR-TK-IN-5
<p>EGFR-TK-IN-5 (Compound NCE 2) is a thiazolyl pyrazoline derivative with significant inhibitory activity and stability against EGFR. It is applicable in tumor research.</p>Fórmula:C26H20ClFN4OSForma y color:SolidPeso molecular:490.98PROTAC EGFR degrader 6
CAS:<p>PROTAC EGFR degrader 6 effectively degrades EGFR Del19 in HCC827 cells (DC50=45.2 nM) and induces apoptosis and G1 arrest.</p>Fórmula:C49H57FN12O5Forma y color:SolidPeso molecular:913.05MP-RM-1
<p>MP-RM-1 is a selective murine monoclonal antibody inhibitor that targets the human epidermal growth factor receptor 3 (ErbB-3). It blocks ErbB-3 activation induced by neuregulin 1 (NRG-1β), facilitates ErbB-3 internalization and degradation, and inhibits downstream signaling pathways like PI3K-Akt. MP-RM-1 shows potential for research on ErbB-3-overexpressing solid tumors such as breast cancer, melanoma, and prostate cancer.</p>Forma y color:Odour LiquidEGFR-IN-144
<p>EGFR-IN-144 (Compound 4B) inhibits EGFR (IC50=0.639 µg/mL) and tubulin polymerization (IC50=7.339 µg/mL). It exhibits cytotoxicity in various cancer cells with a GI50 at the nanomolar level. EGFR-IN-144 reduces the expression of mTOR, TNF-α, and IL-6, causes G1/S phase cell cycle arrest, and induces apoptosis.</p>Fórmula:C20H17Cl2N3O3Forma y color:SolidPeso molecular:418.273SA-VA
<p>SA-VA, an intracellular self-assembled PROTAC featuring azide and alkyne groups, selectively degrades VEGFR-2 and EphB4 proteins within U87 cells.</p>Fórmula:C50H53ClF3N11O7SPureza:98%Forma y color:SolidPeso molecular:1044.54MTX-241F
<p>MTX-241F, a selective small molecule inhibitor, targets members of the EGFR and PI3 kinase families.</p>Fórmula:C20H14ClFN6Pureza:98%Forma y color:SolidPeso molecular:392.82ALK-IN-13
CAS:<p>ALK-IN-13 is an ALK inhibitor.</p>Fórmula:C29H39ClN7O2PForma y color:SolidPeso molecular:584.1Axltide
CAS:<p>Axltide mimics mouse Insulin receptor substrate 1, amino acids 979-989 with sequence KKSRGDYMTMQIG.</p>Fórmula:C63H107N19O20S2Pureza:98%Forma y color:SolidPeso molecular:1514.77VEGFR-2-IN-66
<p>VEGFR-2-IN-66 (Compound 6) is an orally active VEGFR-2 inhibitor with an IC50 of 0.509 µM and an IC50 value of 7.48 μM for inhibiting MCF-7 cell proliferation. Its anticancer activity is exerted through cell cycle arrest, induction of apoptosis (Apoptosis), and modulation of gene expression, making it suitable for breast cancer research.</p>Forma y color:Odour SolidDSPE-PEG2000-GE11
<p>DSPE-PEG2000-GE11 is a PEG compound composed of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells that overexpress EGFR. DSPE-PEG2000-GE11 is utilized in drug delivery.</p>Forma y color:Odour SolidEGFR/BRAFV600E-IN-3
<p>EGFR/BRAFV600E-IN-3 is an inhibitor targeting EGFR, BRAFV600E, and EGFRT790M with IC50 values of 57 nM, 68 nM, and 9.70 nM, respectively.</p>Fórmula:C25H18N4O3Pureza:98%Forma y color:SolidPeso molecular:422.44BW710
<p>BW710 is an orally active inhibitor specifically targeting fibroblast growth factor receptor 2 (FGFR2). It effectively inhibits the proliferation of BaF3-FGFR2 cells with an IC50 value of 2.8 nM. BW710 completely suppresses FGFR2 enzymatic activity and demonstrates selectivity among 75 tyrosine kinases, including FGFR1, FGFR3, and FGFR4, at a 1 μM concentration. Additionally, BW710 impedes FGFR2 signaling and selectively inhibits the proliferation of cancer cells driven by FGFR2. It exhibits promising pharmacokinetic properties, with an oral bioavailability of 29% in mice.</p>Fórmula:C28H29FN6O2SForma y color:SolidPeso molecular:532.63Duligotuzumab
CAS:<p>Duligotuzumab is a dual-targeting anti-EGFR/HER3 mAb that blocks signaling and induces ADCC for tumors with poor prognosis.</p>Pureza:95% - 95%Forma y color:LiquidGSK143
CAS:<p>GSK143: Oral SYK inhibitor, pIC50=7.5, curbs pErk, anti-inflammatory, hinders immune cells in mice.</p>Fórmula:C17H22N6O2Forma y color:SolidPeso molecular:342.403JH-XI-10-02
CAS:<p>JH-XI-10-02 selectively degrades CDK8 (IC50: 159 nM) through proteasome, sparing CDK8 mRNA and CDK19.</p>Fórmula:C53H69N5O9Pureza:98%Forma y color:SolidPeso molecular:920.161Abicipar pegol
CAS:<p>Abicipar pegol is an anti-VEGF DARPin for ocular diseases, reducing retinal thickness and leakage.</p>Forma y color:LiquidSrc Inhibitor 4
<p>Src Inhibitor4 (Compound 18) is a derivative of KX-01 and functions as a Src inhibitor. It effectively disrupts tumor cells, damages microtubules, and induces cell cycle arrest, apoptosis, and immunogenic cell death. After introducing phenol or aniline functional groups, Src Inhibitor4 serves as a payload conjugation site for antibody-drug conjugates, showcasing antitumor activity.</p>Fórmula:C33H34N4O3Forma y color:SolidPeso molecular:534.648PROTAC BTK Degrader-6
CAS:<p>PROTAC BTK Degrader-6 (Compound 15), with a DC50 of 3.18 nM, exhibits anti-inflammatory properties by inhibiting NF-κB activation and suppressing the expression</p>Fórmula:C45H47N11O6Pureza:98%Forma y color:SolidPeso molecular:837.92Varlitinib Tosylate
CAS:<p>Varlitinib Tosylate is a selective and potent inhibitor of ErbB1(EGFR) and ErbB2(HER2).</p>Fórmula:C36H35ClN6O8S3Pureza:98%Forma y color:SolidPeso molecular:811.34EGFR/COX-2-IN-1
<p>EGFR/COX-2-IN-1 is an EGFR/COX-2 inhibitor that effectively targets EGFRWT, EGFRT790M, COX-1, and COX-2 with IC50 values of 0.12, 0.076, 20.1, and 1.52 μM, respectively. It inhibits MCF-7, HT-29, and A-549 cells with IC50 values of 1.20, 5.14, and 14.81 μM, respectively. The compound induces apoptosis by upregulating Bax protein and downregulating Bcl-2 protein levels. Additionally, EGFR/COX-2-IN-1 significantly increases the proportion of cells in the G2/M phase in MCF-7 cells, demonstrating a broad-spectrum antitumor effect.</p>Fórmula:C20H17FN6O2S2Forma y color:SolidPeso molecular:456.52JAK1/STAT3-IN-1
<p>JAK1/STAT3-IN-1 (compound 4f) functions as an anti-atopic dermatitis (AD) agent by inhibiting the JAK1/STAT3 signaling pathway. It has an IC50 value of 2.17 μM for inhibiting NO production. Additionally, JAK1/STAT3-IN-1 improves skin conditions in AD-like mice by reducing inflammatory infiltration, suppressing the expression of p-JAK1/JAK1 and p-STAT3/STAT3, and alleviating the hyperimmune response induced by MC903 (Calcipotriol).</p>Fórmula:C30H33FN4O3SForma y color:SolidPeso molecular:548.67RR-src
CAS:<p>Tyrosine kinase substrate peptide</p>Fórmula:C64H106N22O21Pureza:98%Forma y color:Lyophilized PowderPeso molecular:1519.66MET/PDGFRA-IN-2
<p>MET/PDGFRA-IN-2 (compound 8h) serves as an inhibitor of MET and PDGFRA proteins, promoting apoptosis in cells and impeding the proliferation of MET-positive</p>Fórmula:C29H29N7OPureza:98%Forma y color:SolidPeso molecular:491.59JAK3-IN-14
CAS:<p>JAK3-IN-14 is a potent, selective and orally active FLT3 inhibitor, with IC50s of ∼40, 8, and 4 nM for FLT3-WT, FLT3-D835Y, and FLT3-D835H, respectively.</p>Fórmula:C18H13N3OPureza:98.29%Forma y color:SoildPeso molecular:287.32EGFR/VEGFR2-IN-5
<p>EGFR/VEGFR2-IN-5 (Compound 14) is an orally active dual inhibitor of EGFR and VEGFR2, exhibiting an IC50 value of 1.15 µM for VEGFR2 and 0.28 µM for EGFRT790M. This compound demonstrates significant anticancer activity.</p>Fórmula:C17H15N7O5SForma y color:SolidPeso molecular:429.41EGFR-IN-151
<p>EGFR-IN-151 (Compound 10) inhibits EGFR and its downstream signaling pathways ERK/STAT3. It effectively suppresses the proliferation of various lung cancer cells, with IC50 values of 11.7, 5.19, 7.32, and 1.53 μM for NCI-H1781, HCC827, NCI-H3255, and NCI-H1975, respectively. Additionally, EGFR-IN-151 hinders colony formation and cell migration in H1975, induces G1 phase cell cycle arrest, and triggers apoptosis in H1975 cells.</p>Forma y color:Odour SolidFGFRs-IN-1
<p>FGFRs-IN-1 (Compound A16) is an orally active inhibitor targeting FGFR1/2/3/4, with IC50 values of 2.3, 7, 11, and 163 nM respectively. It also inhibits VEGFR1/2/3, Abl, and Flt3, with IC50 values of 61, 176, 112, 26, and 353 nM. The compound shows weak inhibition of CYP enzymes. FGFRs-IN-1 reduces the expression of α-SMA and collagen I, and it inhibits epithelial-mesenchymal transition (EMT) in A549 cells stimulated by TGF-β1. Additionally, FGFRs-IN-1 demonstrates anti-inflammatory activity in mouse models of lung fibrosis induced by Bleomycin and liver fibrosis induced by CCl4.</p>Fórmula:C28H26Cl2N4O3Forma y color:SolidPeso molecular:537.44MY-1576
<p>MY-1576 is a FAK inhibitor with an IC50 of 8 nM. It activates the Hippo pathway, thereby inhibiting YAP/TAZ regulation. Additionally, MY-1576 effectively suppresses tumor growth in the KYSE30 xenograft mouse model, demonstrates good safety, and efficiently downregulates FAK autophosphorylation and YAP/TAZ levels in vivo.</p>Fórmula:C25H29ClN8O2Forma y color:SolidPeso molecular:509Cetuximab (PBS)
<p>Cetuximab (PBS) is a human IgG1 monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), with a dissociation constant (Kd) of 0.201 nM for EGFR as measured by the SPR method. It exhibits potent antitumor activity.</p>Forma y color:Odour LiquidOK2
<p>OK2, a specific inhibitor of the CCN2/EGFR interaction, effectively disrupts this interaction by binding to the CT domain of CCN2.</p>Fórmula:C42H62N14O9Pureza:98%Forma y color:SolidPeso molecular:907.03Scr-IN-1
<p>Scr-IN-1 (Compound 4e) is a tyrosine kinase inhibitor demonstrating inhibitory activity against HCT-116 and MIA-PaCa-2 cells, with IC50 values of 0.16 μM and 1.16 μM, respectively. It shows selectivity towards HCT-116 cells and MIA-PaCa-2 cells, with a selectivity index (SI) greater than 625 and 86. Scr-IN-1 induces apoptosis in HCT-116 colon cancer cells without altering the proportion of necrotic cells and is a potential novel SRC kinase inhibitor for HCT-116 cells. This compound is suitable for cancer research.</p>Fórmula:C26H16ClF3N2O3Forma y color:SolidPeso molecular:496.87EGFR-IN-86
<p>EGFR-IN-86 (compound 4i), an EGFR inhibitor (IC50: 1.5 nM), demonstrates potent activity against glioblastoma by inducing apoptosis and causing G2/M phase cell</p>Fórmula:C20H21N7O2SPureza:98%Forma y color:SolidPeso molecular:423.49Candidalysin
CAS:<p>Candidalysin is a cytolytic peptide toxin initially isolated from *Candida albicans*, exhibiting both toxic and non-toxic properties. It activates epithelial cell signaling pathways by interacting with the epithelial growth factor receptor (EGFR) on host cells, leading to the activation of matrix metalloproteinases (MMP) and calcium ion influx, which results in inflammatory responses and immune cell recruitment. Additionally, Candidalysin exhibits cytotoxicity by causing membrane damage to host cells.</p>Fórmula:C153H266N38O38S2Forma y color:SolidPeso molecular:3310.11
